Department of Paediatrics, University of Oxford, Oxford, UK.
National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Lancet. 2018 Dec 15;392(10164):2595-2605. doi: 10.1016/S0140-6736(18)31813-0. Epub 2018 Nov 30.
BACKGROUND: Infant pain has immediate and long-term effects but is undertreated because of a paucity of evidence-based analgesics. Although morphine is often used to sedate ventilated infants, its analgesic efficacy is unclear. We aimed to establish whether oral morphine could provide effective and safe analgesia in non-ventilated premature infants for acute procedural pain. METHODS: In this single-centre masked trial, 31 infants at the John Radcliffe Hospital, Oxford, UK, were randomly allocated using a web-based facility with a minimisation algorithm to either 100 μg/kg oral morphine sulphate or placebo 1 h before a clinically required heel lance and retinopathy of prematurity screening examination, on the same occasion. Eligible infants were born prematurely at less than 32 weeks' gestation or with a birthweight lower than 1501 g and had a gestational age of 34-42 weeks at the time of the study. The co-primary outcome measures were the Premature Infant Pain Profile-Revised (PIPP-R) score after retinopathy of prematurity screening and the magnitude of noxious-evoked brain activity after heel lancing. Secondary outcome measures assessed physiological stability and safety. This trial is registered with the European Clinical Trials Database (number 2014-003237-25). FINDINGS: Between Oct 30, 2016, and Nov 17, 2017, 15 infants were randomly allocated to morphine and 16 to placebo; one infant assigned placebo was withdrawn from the study before monitoring began. The predefined stopping boundary was crossed, and trial recruitment stopped because of profound respiratory adverse effects of morphine without suggestion of analgesic efficacy. None of the co-primary outcome measures differed significantly between groups. PIPP-R score after retinopathy of prematurity screening was mean 11·1 (SD 3·2) with morphine and 10·5 (3·4) with placebo (mean difference 0·5, 95% CI -2·0 to 3·0; p=0·66). Noxious-evoked brain activity after heel lancing was median 0·99 (IQR 0·40-1·56) with morphine and 0·75 (0·33-1·22) with placebo (median difference 0·25, 95% CI -0·16 to 0·80; p=0·25). INTERPRETATION: Administration of oral morphine (100 μg/kg) to non-ventilated premature infants has the potential for harm without analgesic efficacy. We do not recommend oral morphine for retinopathy of prematurity screening and strongly advise caution if considering its use for other acute painful procedures in non-ventilated premature infants. FUNDING: Wellcome Trust and National Institute for Health Research.
背景:婴儿疼痛具有即时和长期影响,但由于缺乏循证镇痛药物,因此治疗不足。尽管吗啡常用于镇静通气婴儿,但其镇痛效果尚不清楚。我们旨在确定口服吗啡是否可以为非通气早产儿提供急性手术疼痛的有效和安全镇痛。
方法:在这项单中心盲法试验中,英国牛津约翰拉德克利夫医院的 31 名婴儿使用基于网络的设施和最小化算法随机分配,在需要进行临床足跟穿刺和早产儿视网膜病变筛查检查前 1 小时,分别接受 100μg/kg 硫酸吗啡或安慰剂。合格的婴儿出生时胎龄不足 32 周或出生体重低于 1501g,在研究时胎龄为 34-42 周。主要结局指标是早产儿疼痛概况修订版(PIPP-R)评分在早产儿视网膜病变筛查后和足跟穿刺后有害诱发的大脑活动幅度。次要结局指标评估生理稳定性和安全性。这项试验在欧洲临床试验数据库(编号 2014-003237-25)注册。
结果:2016 年 10 月 30 日至 2017 年 11 月 17 日,15 名婴儿随机分配至吗啡组,16 名婴儿分配至安慰剂组;1 名分配至安慰剂的婴儿在开始监测前退出研究。由于吗啡的严重呼吸不良反应而越过了预设的停止边界,并停止了试验招募,而没有提示镇痛效果。两组间主要结局指标均无显著差异。早产儿视网膜病变筛查后的 PIPP-R 评分吗啡组为 11.1(SD 3.2),安慰剂组为 10.5(3.4)(平均差 0.5,95%CI-2.0 至 3.0;p=0.66)。足跟穿刺后有害诱发的大脑活动吗啡组中位数为 0.99(IQR 0.40-1.56),安慰剂组中位数为 0.75(0.33-1.22)(中位数差 0.25,95%CI-0.16 至 0.80;p=0.25)。
解释:非通气早产儿口服吗啡(100μg/kg)可能会造成伤害,而没有镇痛作用。我们不建议将吗啡用于早产儿视网膜病变筛查,如果考虑将其用于非通气早产儿的其他急性疼痛手术,我们强烈建议谨慎使用。
资助:惠康信托基金会和英国国家健康研究所。
Cochrane Database Syst Rev. 2023-6-23
Cochrane Database Syst Rev. 2015-6-25
Cochrane Database Syst Rev. 2023-4-5
Cochrane Database Syst Rev. 2016-10-7
Cochrane Database Syst Rev. 2023-4-4
Int J Crit Illn Inj Sci. 2024
Eng Microbiol. 2022-12-13
Asia Pac J Ophthalmol (Phila). 2018-6-11
Pediatrics. 2018-6-1
Sci Transl Med. 2017-5-3
Curr Opin Support Palliat Care. 2017-6
Expert Rev Clin Pharmacol. 2017-1
Clinics (Sao Paulo). 2016-8